These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 27456922)

  • 1. A New Combination of Idarubicin, Etoposide and Cytarabine in Untreated Acute Non-Lymphoblastic Leukemia.
    Carella AM; Gaozza E; Piatti G; Nati S; Pungoltno E; Santini G; Giordano D; Cerri R; Risso M; Rossi E; Spriano M; Coingiu A; Carlier P; Raffo MR; Damagio E; Bacigalupo A; Marmont AM
    Leuk Lymphoma; 1990; 2(5):317-22. PubMed ID: 27456922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarubicin in combination with etoposide and cytarabine in adult untreated acute non lymphoblastic leukemia.
    Carella AM; Martinengo M; Santini G; Gaozza E; Damasio E; Giordano D; Nati S; Congiu A; Cerri R; Risso M
    Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1673-8. PubMed ID: 3480803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
    Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
    Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractionated total body irradiation plus high-dose VP-16 prior to allogeneic bone marrow transplantation in children with poor risk acute leukaemias.
    Suttorp M; Schmitz N; Leuschner S; Appelt M; Rister M; Schaub J
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():144-8. PubMed ID: 2697428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation.
    Sierra J; Brunet S; Grañena A; Olivé T; Bueno J; Ribera JM; Petit J; Besses C; Llorente A; Guardia R; Macía J; Rovira M; Badell I; Vela E; Díaz de Heredia C; Vivancos P; Carreras E; Feliu E; Montserrat E; Julía A; Cubells J; Rozman C; Domingo A; Ortega JJ
    J Clin Oncol; 1996 Apr; 14(4):1353-63. PubMed ID: 8648394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
    Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML.
    Harousseau JL; Pignon B; Dufour P; Ifrah N; Solary E; Abgrall JF; Milpied N; Desablens B; Guyotat D; Herve P
    Leukemia; 1992; 6 Suppl 2():120-3. PubMed ID: 1578912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
    Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
    Miggiano MC; Gherlinzoni F; Rosti G; Bandini G; Visani G; Fiacchini M; Ricci P; Testoni N; Motta MR; Geromin A; Rizzi S; Belardinelli A; Mangianti S; Manfroi S; Tura S
    Leukemia; 1996 Mar; 10(3):402-9. PubMed ID: 8642854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
    Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
    Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarubicin in the therapy of acute myeloid leukemia: final analysis in 57 previously untreated patients.
    Lambertenghi Deliliers G; Annaloro C; Oriani A; Pozzoli E; Cortelezzi A; Cortellaro M; Mozzana R; Della Volpe A; Soligo D; Cofrancesco E
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):27-33. PubMed ID: 8290969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.
    Deliliers GL; Annaloro C; Oriani A; Della Volpe A; Boschetti C; Cortelezzi A; Maiolo AT
    Ann Ital Med Int; 1998; 13(3):146-51. PubMed ID: 9859570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.
    Thomas X; Le Q; Botton Sd; Raffoux E; Chelghoum Y; Pautas C; Dreyfus F; Dhedin N; Vekhoff A; Troncy J; Pigneux A; Revel Td; Reman O; Travade P; Thiebaut A; Guerci A; Elhamri M; Fenaux P; Dombret H; Michallet M
    Leuk Lymphoma; 2005 Jul; 46(7):1007-16. PubMed ID: 16019551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic and autologous bone marrow transplantation in AML in first remission. The Spanish experience.
    Ortega JJ; Olivé T; Díaz de Heredia C; Coll MT; Bastida P; Massuet L
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():53-8. PubMed ID: 8932800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
    Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
    J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia.
    Kantarjian HM; Walters RS; Keating MJ; Smith TL; O'Brien S; Estey EH; Huh YO; Spinolo J; Dicke K; Barlogie B
    J Clin Oncol; 1990 Jun; 8(6):994-1004. PubMed ID: 2189958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
    Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.